MedWatch

Eli Lilly on tirzepatide data: Surpasses our expectations

During a teleconference on Tuesday, Eli Lilly stated that the pharmaceutical company has great expectations for the drug candidate tirzepatide against type 2 diabetes.

Photo: Mike Segar/Reuters/Ritzau Scanpix

US pharmaceutical company Eli Lilly has great expectations for the drug candidate tirzepatide now that results from the firm's Surpass program are in.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs